Benitec Biopharma (BNTC) Stock Price, News & Analysis

Company Overview

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

Key Stats

• Today's Range: $14.53 to $15.29
• 50-Day Range: $9.70 to $14.80
• 52-Week Range: $4.75 to $15.29
• Volume: 61,026 shs
• Average Volume: 32,435 shs
• Market Capitalization: $351.06 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $24.43
• Consensus Rating: Buy

Benitec Biopharma Stock Analysis - MarketRank™

Benitec Biopharma scored higher than 50% of companies evaluated by MarketBeat, and ranked 593rd out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Benitec Biopharma has received a consensus rating of Buy. The company's average rating score is 3.22, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Benitec Biopharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Benitec Biopharma are expected to decrease in the coming year, from ($1.48) to ($2.31) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Benitec Biopharma is -9.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Benitec Biopharma is -9.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Benitec Biopharma has a P/B Ratio of 4.62. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.76% of the float of Benitec Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Benitec Biopharma has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Benitec Biopharma has recently increased by 17.55%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Benitec Biopharma does not currently pay a dividend.

Dividend Growth

Benitec Biopharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.76% of the float of Benitec Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Benitec Biopharma has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Benitec Biopharma has recently increased by 17.55%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.71

News Sentiment

Benitec Biopharma has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Benitec Biopharma this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for BNTC on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Benitec Biopharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $301,972.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 1.30% of the stock of Benitec Biopharma is held by insiders.

Percentage Held by Institutions

52.19% of the stock of Benitec Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

BNTC Stock Analysis - Frequently Asked Questions

How have BNTC shares performed this year?

Benitec Biopharma's stock was trading at $12.63 at the beginning of the year. Since then, BNTC stock has increased by 18.5% and is now trading at $14.97.
View the best growth stocks for 2025 here.

How were Benitec Biopharma's earnings last quarter?

Benitec Biopharma Inc. (NASDAQ:BNTC) issued its quarterly earnings results on Friday, February, 14th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.55) by $0.19.

When did Benitec Biopharma's stock split?

Shares of Benitec Biopharma reverse split on the morning of Wednesday, July 26th 2023. The 1-17 reverse split was announced on Wednesday, July 26th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 26th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

When did Benitec Biopharma IPO?

Benitec Biopharma (BNTC) raised $0 in an initial public offering on Thursday, August 6th 2015. The company issued 0 shares at a price of $0.00 per share. BMO Capital Markets and Maxim Group LLC served as the underwriters for the IPO and Roth Capital Partners was co-manager.

Who are Benitec Biopharma's major shareholders?

Top institutional investors of Benitec Biopharma include Suvretta Capital Management LLC (38.59%), Franklin Resources Inc. (12.66%), Janus Henderson Group PLC (11.27%) and Adage Capital Partners GP L.L.C. (8.49%).
View institutional ownership trends.

How do I buy shares of Benitec Biopharma?

Shares of BNTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Benitec Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Benitec Biopharma investors own include Amarin (AMRN), Pfizer (PFE), ADMA Biologics (ADMA), AVEO Pharmaceuticals (AVEO), BioLineRx (BLRX), Exelixis (EXEL) and Sorrento Therapeutics (SRNE).

Company Calendar

• Last Earnings: 2/14/2025
• Today: 3/15/2025
• Next Earnings (Estimated): 5/12/2025
• Fiscal Year End: 6/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BNTC
• CIK: 1808898
• Web: www.benitec.com
• Phone: 510-780-0819
• Fax: 61 (0)3 9966-9923
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $24.43
• High Stock Price Target: $35.00
• Low Stock Price Target: $13.00
• Potential Upside/Downside: +63.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.22
• Research Coverage: 9 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.51)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-21,750,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -44.61%
• Return on Assets: -41.25%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 25.48
• Quick Ratio: 15.01

Sales & Book Value

• Annual Sales: $80,000.00
• Price / Sales: 4,388.27
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.24 per share
• Price / Book: 4.62

Miscellaneous

• Outstanding Shares: 23,451,000
• Free Float: 23,146,000
• Market Cap: $351.06 million
• Optionable: No Data
• Beta: 0.92